Navigation Links
Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/12/2009

ber 31, 2008 2007 2008 2007 REVENUES Royalty $2,007 $2,103 $4,085 $4,084 Technology sale and collaboration services 1,484 1,560 2,971 3,479 Total revenues 3,491 3,663 7,056 7,563 EXPENSES Research and development 10,392 7,416 15,844 12,877 General and administrative 1,201 1,912 2,532 3,571 Total expenses 11,593 9,328 18,376 16,448 Operating loss (8,102) (5,665) (11,320) (8,885) Interest income 264 452 513 479 Gain on sale of long-term investment - - 170 - Interest expense, including non-cash amortization of $1,748 and $2,336 discount on notes for the three and six months ended December 31, 2007, respectively - (1,847) - (2,478) Non-cash gain on change in fair value of warrants - 177 37 3,079 NET LOSS $(7,838) $(6,883) $(10,600) $(7,805) BASIC AND DILUTED NET LOSS PER SHARE $(0.29) $(0.36) $(0.39) $(0.65) Shares used in basic and diluted net loss per share calculation 26,924 19,313 26,924 12,042




                           SELECTED BALANCE SHEET DATA
                                 (in thousands)

                                         December 31,  June 30,
                                            2008         2008
                                         (unaudited)   (Note 1)

      Cash and cash equivalents            $6,914       $27,941
      Short-term investments               16,400    
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Suspension of Viprinex Development
3. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
4. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
5. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
6. Neurobiological Technologies Sets Date for First Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
9. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
11. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
(Date:7/10/2014)... lithium-ion batteries that power our laptops and electric vehicles ... single charge with the help of a sponge-like silicon ... replace the graphite traditionally used in one of the ... the energy storage capacity of graphite. A paper describing ... published today in Nature Communications . , "Silicon ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... to Divest Non-Strategic Assets and ... Financial Performance, NATICK, Mass., Aug. 16 Boston Scientific,Corporation ... the sale,of its Cardiac Surgery and Vascular Surgery businesses as ... and divest those,considered non- strategic, and to strengthen its operating ...
... FRANCISCO, Calif., Aug. 16 Anesiva,Inc. (Nasdaq: ... the,Zingo(TM) development program before the markets open tomorrow. ... at 8:30 a.m. Eastern Time,tomorrow to discuss the ... live audio webcast by dialing,800-340-6289 (international dial: 706-634-1538) ...
... is First Commercial Product for Anesiva - ... for Today at 8:30 a.m. ET -, SOUTH ... ANSV ) announced today that the U.S. Food and ... injection system, which provides rapid,topical, local analgesia to reduce ...
Cached Biology Technology:Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 3Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
(Date:7/10/2014)... main organization of the International Science and Business Belt ... of researchers, led by professor Won Do Heo, have ... that can remotely control specific receptors by light. They ... succeeded with neuronal differentiation inducement. , The most significant ... light to activate neuronal functions without the need of ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New optogenetic tool for controlling neuronal signalling by blue light 2
... Climate change, a recent hot topic when studying the ... another important factor to this global phenomenon is still ... to see the possible effects of climate change on ... waters, and groundwater are responding to climate change. ...
... When the space shuttle Endeavour touched down at ... Medical Branch at Galveston microbiology and immunology department chairman ... to a reunion with some of its passengers. ... were Streptococcus pneumoniae bacteria, members of a species commonly ...
... recently physicians have had to rely on time-consuming and ... diseases such as multiple sclerosis, Alzheimer,s and schizophrenia. ... Journal of Neural Engineering suggests that we could soon ... diseases by analysing the tiny magnetic fields produced by ...
Cached Biology News:Climate change goes underground 2Climate change goes underground 3Shuttle brings space-grown strep bacteria back for study 2Shuttle brings space-grown strep bacteria back for study 360 second test could help early diagnosis of common brain diseases 2
...
... Virgin, optically clear polystyrene with frosted ... coordinates for cell counting. 100% integrity ... a new product number, created to ... showing no availability yet, please order ...
... Corning CellBIND surface is produced by ... a more hydrophilic surface giving more ... growth and yields. CellBIND enhances cell ... including reduced serum or serum-free medium. ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: